Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.30%171.811.3%$496.66m
BIIBBiogen Inc.
-0.97%232.761.3%$475.70m
CELGCelgene Corporation
-0.48%95.901.3%$455.04m
GILDGilead Sciences, Inc.
1.07%67.210.9%$439.36m
ILMNIllumina, Inc.
-0.01%312.803.5%$317.67m
REGNRegeneron Pharmaceuticals, Inc.
-1.07%316.662.6%$295.41m
AAgilent Technologies, Inc.
-2.25%66.441.6%$202.98m
VRTXVertex Pharmaceuticals Incorporated
-0.40%171.681.9%$180.45m
EXASExact Sciences Corporation
-2.01%93.0025.3%$160.37m
ALXNAlexion Pharmaceuticals, Inc.
-1.22%126.002.0%$147.82m
BMRNBioMarin Pharmaceutical Inc.
-0.64%87.134.3%$117.79m
SRPTSarepta Therapeutics, Inc.
-1.24%120.1214.7%$110.76m
INCYIncyte Corporation
0.77%79.632.5%$106.54m
IONSIonis Pharmaceuticals, Inc.
-1.63%67.458.2%$97.14m
ALNYAlnylam Pharmaceuticals, Inc
-1.33%66.919.2%$93.68m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.